Triomics, a provider of a patient recruitment platform for oncology-related clinical trials, has raised USD 15 million in a venture funding round, which saw participation from investors including Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator.

The raised funds will be used to develop the company’s platform and roll it out to new customers. The company notes that as of May 2024, its solution is being used by six cancer centers and hospitals, a number it plans to double by the end of the year.

Triomics has developed an AI-based platform to enhance cancer care by helping trial operators secure patients for clinical trials, prevent delays in patient care, eliminate backlogs and inefficiencies, and eliminate provider burnout. The company’s work revolves around developing an AI model, "OncoLLM," trained specifically to analyze unstructured oncology data, greatly reducing time wasted on manual data analysis while improving accuracy in patient-trial matching.